naproxen delayed-release / Generic mfg. - LARVOL DELTA

A multi-compartment pulsatile drug delivery system for sequential release: in vitro and in vivo evaluation. (PubMed, Drug Deliv Transl Res) - "The in vitro dissolution displayed immediate release of esomeprazole and delayed release of naproxen with Tlag of 11.33 ± 1.37 h...The time to maximum plasma concentration (Tmax) of esomeprazole was 0.67 ± 0.67 h, whereas the Tmax of naproxen was 9.83 ± 2.40 h with a Tlag of 4.75 ± 1.17 h. These findings demonstrate that this modular 3D-printed platform, combined with conventional tablets, provides controlled and sequential drug delivery, thereby supporting patient-tailored therapeutic regimens."

Journal • Preclinical

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP (GlobeNewswire) - "ANI Pharmaceuticals, Inc...announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP. ANI’s Naproxen Delayed-Release Tablets is the generic version of the reference listed drug (RLD) EC-Naprosyn."

FDA approval • Generic launch • CNS Disorders • Pain

Pediapharm announces annual audited financial results-operating profit of $1.9 million in Q4 and Improvement of $3.7 million in annual operating loss (MarketWired) - "Sold United States rights to Naproxen Suspension in a transaction valued at US$4.25 million with Atnahs Pharma US Limited, who also owns the global rights to the Naprosyn® brand. First payment of US$2.25 million was received in February 2016 while second and final payment of US$2 million was received in May 2016."

Financing • Licensing / partnership • Ankylosing Spondylitis